Oragenics Receives HREC Approval for Phase IIa Clinical Trial of ONP-002 as a Treatment for Concussion and Mild Traumatic Brain Injury in Australia (Globe Newswire)
UF Innovate | Accelerate graduate Oragenics has received final ethics approval in Australia to begin its Phase IIa clinical trial of ONP-002, an intranasal therapy being developed to treat concussion and mild traumatic brain injury.
Oragenics Partners With DUCK FLATS Pharma To Support FDA IND Readiness and Clinical Trial Design for Concussion Program (Globe Newswire)
UF Innovate | Accelerate graduate Oragenics announced it has engaged DUCK FLATS Pharma as its U.S. Investigational New Drug (IND) readiness and regulatory execution partner to support FDA-facing preparation and clinical trial design as the Company advances its novel intranasal concussion therapy toward U.S.-based development.
Oragenics Selects Southern Star Research As Clinical Research Organization for ONP-002 Phase IIa Trial
UF Innovate | Accelerate graduate Oragenics, Inc., announced the selection of Southern Star Research as its Clinical Research Organization (CRO) for the upcoming Phase IIa clinical trial of ONP-002, the company’s lead drug candidate for concussion.
Oragenics, Inc. Announces Approval To Initiate Phase II Concussion Drug Trial in Australia
UF Innovate | Accelerate graduate Oragenics announced that it has received approval from the Human Research Ethics Committee (HREC) in Australia to initiate a Phase II clinical trial evaluating ONP-002 for the treatment of mild traumatic brain injury (mTBI).
Oragenics, Inc. To Participate at the 15th Annual Traumatic Brain Injury Conference
UF Innovate | Accelerate graduate Oragenics, Inc., a biotechnology company developing novel intranasal therapies for concussion and other brain-related conditions, announced its participation in the 15th Annual Traumatic Brain Injury Conference.
Oragenics, Inc. Submits Investigator’s Brochure for Phase II Clinical Trial of ONP-002 in Mild Traumatic Brain Injury
UF Innovate | Accelerate graduate Oragenics, Inc. announced the submission of its Investigator’s Brochure (IB) application in preparation for its Phase II clinical trial using ONP-002 in Australia.
Oragenics, Inc. Announces Partnership With BRAINBox Solutions To Revolutionize Concussion Diagnosis and Treatment
UF Innovate | Accelerate graduate Oragenics, Inc., a biotechnology company advancing innovative treatments for concussion and brain-related health conditions, announced a strategic partnership with BRAINBox Solutions, a leader in multi-modality diagnostics for traumatic brain injury (TBI).
Oragenics Inc. Announces Concussion Drug, ONP-002, Successfully Clears FDA-Required Cardiotoxicity Testing
UF Innovate | Accelerate graduate Oragenics, Inc., a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, announced its lead candidate for treating concussion successfully completed a study that indicates ONP-002 does not cause cardiotoxicity.
Odyssey Group International’s Planned Acquisition of Concussion Drug from Prevacus, Inc. Enhances Delivery Capabilities with Nasal Therapeutic
Odyssey Group International is circulating a video to better define its drug candidate PRV-002, a therapeutic compound drug to treat concussion (mild traumatic brain injury (mTBI), from UF Innovate | Sid Martin Biotech alum Prevacus Inc. Odyssey is expected to acquire PRV-002 by the end of February.